Dr Marc Lemaître
Marc Lemaître holds a degree in Organic Chemistry and a PhD in Biochemistry from the University of Liège, Belgium. Since 1985 Marc’s professional interests has been the study of Nucleic Acids for therapeutic and diagnostic applications. After 5 years of post-doc research including 2 years at the Pasteur institute in the team of Nobel Prize Luc Montagnier, Marc held positions of increasing seniority in R&D, operations, business development, and general management within CMO’s, Pharma and Biotech companies.
Based in the USA since 2006 he was CEO of Girindus America [Cincinnati, OH – 2009-2013], a CMO with a focus on the cGMP manufacture of oligonucleotides for therapeutic applications until its acquisition by AVECIA.
Since 2013 Marc is working as independent consultant specialized in CMC and working mostly with start-up and Pharma companies developing therapeutic oligonucleotides and some peptides.
He is member of the Board of Director of the Oligonucleotide Therapeutics Society since 2015.
Cutting-Edge Cancer Immunotherapy
60F avenue Rockefeller
69008 Lyon, FRANCE